CoLucid Pharmaceuticals, a late-stage biotech developing therapies for acute migraines, raised $55 million by offering 5.5 million shares at $10, below its original $13 to $15 range. The company increased the shares offered, dropped the IPO price to $10 and increased insider buying to $25 million (45% of the deal) in an amendment filed with the SEC on Monday.
CoLucid Pharmaceuticals will list on the NASDAQ under the symbol CLCD. Piper Jaffray and Stifel acted as joint bookrunners on the deal.
